Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Entrada Therapeutics, Inc. TRDA

Set alert

Price alert · TRDA

All alert types
5.11 USD +0.58 +12.68%

At close · Nov 2

5.07 -0.04 -0.78%

After hours · Nov 2, 4:00 PM ET

Bid
5.11 × 2
Ask
5.12 × 2
4.44 Day range 5.13
4.11 52-week range 16.45
YTD
-50.29%
1 year
-26.47%
Open
4.58
Prev close
4.54
Mkt cap
198.97M
Vol
652.14K
Avg vol
344.29K
EPS
-4.47
P/E
0.00
Div yield
0.00%
More statistics
Low
4.44
High
5.13
Forward P/E
-5.54
Beta
-0.27
Short ratio
11.43
Inst. own
80.85%
Dividend
0.00
Ex-div date
Earnings
Aug 13, 2024
50-d avg
18.48
200-d avg
15.77
1y target
26.43

3M chart

Chart tools
Interval
1m5m15m30m

Signals (17)
NameDateAgo
MACD: Buy SignalOct 28, 20265 days ago
MACD: Sell SignalOct 27, 20266 days ago
MACD: Buy SignalOct 26, 20261 week ago
RSI: OversoldOct 16, 20262 weeks ago
RSI: OversoldOct 13, 20262 weeks ago
RSI: OversoldOct 2, 20261 month ago
SMA: BearishSep 15, 20261 month ago
SMA: BullishSep 14, 20261 month ago
SMA: BearishSep 10, 20261 month ago
SMA: BearishSep 9, 20261 month ago
SMA: BearishAug 28, 20262 months ago
SMA: BullishAug 27, 20262 months ago
MACD: Sell SignalAug 27, 20262 months ago
SMA: BearishAug 26, 20262 months ago
SMA: BullishAug 10, 20262 months ago
SMA: BearishAug 6, 20262 months ago
SMA: BullishAug 3, 20263 months ago

Financial health

Altman Z-Score

-0.80 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

1 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

FMP rating

B-2 / 5 overall

  • DCF 4
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 3
  • P/E 1
  • P/B 4

Valuation

P/E -3.0×
FY 2019: -5.4×FY 2020: -28.5×FY 2021: -10.7×FY 2022: -4.8×FY 2023: -75.4×FY 2024: 9.8×FY 2025: -3.0×
FY 2019 5y median -4.8× FY 2025
P/S 16.7×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 3.9×FY 2024: 3.1×FY 2025: 16.7×
FY 2019 5y median 3.1× FY 2025
P/B 1.4×
FY 2019: -1.6×FY 2020: -18.0×FY 2021: 1.8×FY 2022: 2.0×FY 2023: 2.1×FY 2024: 1.5×FY 2025: 1.4×
FY 2019 5y median 1.8× FY 2025
P/FCF -3.3×
FY 2019: -2.2×FY 2020: -26.8×FY 2021: -9.6×FY 2022: -4.4×FY 2023: 3.7×FY 2024: -14.4×FY 2025: -3.3×
FY 2019 5y median -4.4× FY 2025
EV/EBITDA -2.8×
FY 2019: -0.7×FY 2020: -27.1×FY 2021: -4.9×FY 2022: -4.5×FY 2023: 33.5×FY 2024: 8.6×FY 2025: -2.8×
FY 2019 5y median -2.8× FY 2025
EV/Sales 15.2×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 3.9×FY 2024: 2.9×FY 2025: 15.2×
FY 2019 5y median 2.9× FY 2025
FCF Yield -30.5%
FY 2019: -45.5%FY 2020: -3.7%FY 2021: -10.4%FY 2022: -22.8%FY 2023: 26.9%FY 2024: -6.9%FY 2025: -30.5%
FY 2019 5y median -10.4% FY 2025

Profitability

Gross Margin 83.9%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 100.0%FY 2024: 100.0%FY 2025: 83.9%
FY 2019 5y median 83.9% FY 2025
Operating Margin -613.7%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: -2.5%FY 2024: 22.3%FY 2025: -613.7%
FY 2019 5y median 0.0% FY 2025
Net Margin -565.5%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: -5.2%FY 2024: 31.1%FY 2025: -565.5%
FY 2019 5y median 0.0% FY 2025
ROE -47.0%
FY 2019: 30.0%FY 2020: 63.9%FY 2021: -17.1%FY 2022: -44.5%FY 2023: -2.8%FY 2024: 15.3%FY 2025: -47.0%
FY 2019 5y median -17.1% FY 2025
ROIC -43.7%
FY 2019: -72.5%FY 2020: -66.4%FY 2021: -17.1%FY 2022: -40.8%FY 2023: 0.6%FY 2024: 9.4%FY 2025: -43.7%
FY 2019 5y median -17.1% FY 2025
ROA -38.1%
FY 2019: -25.5%FY 2020: -60.9%FY 2021: -16.7%FY 2022: -37.5%FY 2023: -1.4%FY 2024: 12.5%FY 2025: -38.1%
FY 2019 5y median -16.7% FY 2025

Growth (YoY)

Revenue -87.9%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 63.4%FY 2025: -87.9%
FY 2019 FY 2025
Operating Income -431.8%
FY 2019: 0.0%FY 2020: -125.5%FY 2021: -91.7%FY 2022: -90.2%FY 2023: 96.7%FY 2024: 1586.7%FY 2025: -431.8%
FY 2019 FY 2025
EPS (diluted) -306.5%
FY 2019: 0.0%FY 2020: 81.1%FY 2021: -90.5%FY 2022: -74.4%FY 2023: 92.8%FY 2024: 940.0%FY 2025: -306.5%
FY 2019 FY 2025
Free Cash Flow -189.7%
FY 2019: 0.0%FY 2020: -144.0%FY 2021: -98.8%FY 2022: -74.4%FY 2023: 238.8%FY 2024: -133.3%FY 2025: -189.7%
FY 2019 FY 2025

Financial Health

Current Ratio 12.5×
FY 2019: 9.1×FY 2020: 11.9×FY 2021: 44.5×FY 2022: 9.6×FY 2023: 2.3×FY 2024: 11.1×FY 2025: 12.5×
FY 2019 5y median 11.1× FY 2025
Quick Ratio 12.5×
FY 2019: 9.1×FY 2020: 11.9×FY 2021: 44.5×FY 2022: 9.6×FY 2023: 2.3×FY 2024: 11.1×FY 2025: 12.5×
FY 2019 5y median 11.1× FY 2025
Debt / Equity 0.2×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.1×FY 2023: 0.3×FY 2024: 0.1×FY 2025: 0.2×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA 0.3×
FY 2019: 1.4×FY 2020: 1.5×FY 2021: 5.8×FY 2022: 0.2×FY 2023: 0.0×FY 2024: -0.6×FY 2025: 0.3×
FY 2019 5y median 0.2× FY 2025
Interest Coverage 0.0×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: -36.9×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2019 5y median 0.0× FY 2025

Dividends

Dividend Yield 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31